- Conditions
- Endometriosis-related Pain
- Interventions
- Gefapixant, Placebo, Naproxen
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years to 49 Years · Female only
- Enrollment
- 187 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 30
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Scottsdale, Arizona + 25 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–91
of 91
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Endometriosis (Diagnosis)
- Interventions
- TENS
- Device
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- 10 Years to 21 Years · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Pelvic Pain, Endometriosis, Chronic Pelvic Pain
- Interventions
- Reinforcement Learning (RL)-Based Personalized Exercise Recommendations, Generic Exercise Recommendation
- Behavioral
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years to 55 Years · Female only
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Migraine, Endometriosis
- Interventions
- Thermal stimuli, Pressure stimuli, Pain ratings, Conditioned pain modulation (CPM) response, Hormonal assessment
- Device · Behavioral · Biological
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 12 Years to 45 Years · Female only
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Pelvic Pain, Endometriosis
- Interventions
- Psychophysical assessment, Psychophysical assessments of experimental pain, Blood, urine and saliva samples, Biopsy and surgery-related data.
- Other · Behavioral · Diagnostic Test + 1 more
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 12 Years to 45 Years · Female only
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Chronic Pain, Acute Pain, Post Operative Pain, Fibromyalgia, Primary, Fibromyalgia, Secondary, Fibromyalgia, Irritable Bowel Syndrome, Chronic Headache Disorder, Chronic Migraine, Chronic Pelvic Pain Syndrome, Temporomandibular Joint Disorders, Endometriosis-related Pain, Arthritis, Chronic Low-back Pain, Failed Back Surgery Syndrome, Post Herpetic Neuralgia, Neuropathic Pain, Painful Diabetic Neuropathy, Painful Bladder Syndrome, Trauma-related Wound, Trauma, Multiple, Chronic Pain Syndrome, Chronic Shoulder Pain
- Interventions
- SOMA pain manager smartphone application
- Device
- Lead sponsor
- Brown University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 800 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Providence, Rhode Island
- Conditions
- Endometriosis
- Interventions
- 75 mg linzagolix tablet, 200 mg linzagolix tablet, Add-back capsule (E2 1 mg / NETA 0.5 mg), Placebo tablet to match 75 mg linzagolix tablet, Placebo tablet to match 200 mg linzagolix tablet, Placebo capsule to match Add-back capsule
- Drug
- Lead sponsor
- Kissei Pharmaceutical Co., Ltd.
- Industry
- Eligibility
- 18 Years to 49 Years · Female only
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 107
- States / cities
- Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 79 more
- Conditions
- Endometriosis Related Pain
- Interventions
- Relugolix, Estradiol/norethindrone acetate, Estradiol/norethindrone acetate placebo, Relugolix placebo
- Drug
- Lead sponsor
- Myovant Sciences GmbH
- Industry
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 623 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 41
- States / cities
- Andalusia, Alabama • Washington D.C., District of Columbia • Aventura, Florida + 36 more
- Conditions
- Endometriosis, Dyspareunia, Pelvic Pain
- Interventions
- Transvaginal photobiomodulation, Sham therapy
- Device
- Lead sponsor
- Medstar Health Research Institute
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 6 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 6
- States / cities
- Washington D.C., District of Columbia • Mitchellville, Maryland • Rockville, Maryland + 1 more
- Conditions
- Endometriosis
- Interventions
- Observational study, no intervention
- Other
- Lead sponsor
- Aspira Women's Health
- Industry
- Eligibility
- 14 Years to 50 Years · Female only
- Enrollment
- 1,200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 10
- States / cities
- Chandler, Arizona • Burbank, California • Newark, Delaware + 7 more
- Conditions
- Endometriosis
- Interventions
- Naltrexone, Norethindrone Acetate, Placebo
- Drug
- Lead sponsor
- Milton S. Hershey Medical Center
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Hershey, Pennsylvania
- Conditions
- Endometriosis, Ovarian Hyperstimulation
- Interventions
- Placebo oral tablet, Letrozole
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years to 42 Years · Female only
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2025
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Endometriosis-related Pain
- Interventions
- Quinagolide 360 µg, Quinagolide 720 µg, Quinagolide 1080 µg, Placebo
- Drug
- Lead sponsor
- Ferring Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 43
- States / cities
- Mesa, Arizona • Little Rock, Arkansas • San Diego, California + 36 more
- Conditions
- Endometriosis
- Interventions
- Not listed
- Lead sponsor
- Biofourmis Singapore Pte Ltd.
- Industry
- Eligibility
- 21 Years to 50 Years · Female only
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 2
- States / cities
- Phoenix, Arizona • Rochester, Minnesota
- Conditions
- Dysmenorrhea, Dyspareunia, Endometriosis, Pelvic Pain
- Interventions
- ERB-041
- Drug
- Lead sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006
- U.S. locations
- 49
- States / cities
- Montgomery, Alabama • Chandler, Arizona • Phoenix, Arizona + 41 more
- Conditions
- Endometriosis
- Interventions
- HMI-115, Placebo
- Drug
- Lead sponsor
- Hope Medicine (Nanjing) Co., Ltd
- Industry
- Eligibility
- 18 Years to 49 Years · Female only
- Enrollment
- 142 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 2
- States / cities
- Draper, Utah • Norfolk, Virginia
- Conditions
- Endometriosis, Endometriosis-related Pain
- Interventions
- Rimegepant 75 MG, Placebo
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Chronic Pelvic Pain, Endometriosis
- Interventions
- My Pelvic Plan Website, Control Group website
- Behavioral
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Endometriosis, Pelvic Pain
- Interventions
- Ovira Transcutaneous Electrical Nerve Stimulation Unit
- Device
- Lead sponsor
- Milton S. Hershey Medical Center
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Hershey, Pennsylvania